Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A note on sample size calculation in bioequivalence trials.

Dieter Hauschke

    Journal of Pharmacokinetics and Pharmacodynamics
    |August 27, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer.

    Breast care (Basel, Switzerland)·2017
    Same author

    Randomized Comparison of Oral P2Y<sub>12</sub>-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor: The ExcelsiorLOAD2 Trial.

    JACC. Cardiovascular interventions·2017
    Same author

    Results of a randomized controlled trial analyzing telemedically supported case management in the first year after living donor kidney transplantation - a budget impact analysis from the healthcare perspective.

    Health economics review·2017
    Same author

    Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.

    Histochemistry and cell biology·2016
    Same author

    Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro.

    American journal of cancer research·2016
    Same author

    Gdf-15 deficiency does not alter vulnerability of nigrostriatal dopaminergic system in MPTP-intoxicated mice.

    Cell and tissue research·2016
    Same journal

    Cohort population analysis of sparse data: Dexamethasone pharmacokinetics in mother and fetus based on blood sampling at birth.

    Journal of pharmacokinetics and pharmacodynamics·2026
    Same journal

    Bridging the operational gap in population pharmacokinetic-pharmacodynamic analysis: an international perspective on the 2025 Chinese group standard.

    Journal of pharmacokinetics and pharmacodynamics·2026
    Same journal

    Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

    Journal of pharmacokinetics and pharmacodynamics·2026
    Same journal

    Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

    Journal of pharmacokinetics and pharmacodynamics·2026
    Same journal

    Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

    Journal of pharmacokinetics and pharmacodynamics·2026
    Same journal

    Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

    Journal of pharmacokinetics and pharmacodynamics·2026
    See all related articles

    This review examines statistical methods for sample size calculations in bioequivalence trials. It compares lognormal distribution assumptions in multiplicative models with recent normality-based methods for additive models.

    Area of Science:

    • Pharmacokinetics and Biostatistics
    • Regulatory Science

    Background:

    • Bioequivalence trials traditionally employ multiplicative models, assuming lognormal distribution based on pharmacokinetic principles.
    • Recent advancements introduce statistical methods for sample size calculation under an additive model, assuming normality.

    Discussion:

    • This review critically evaluates the statistical and regulatory implications of both multiplicative (lognormal) and additive (normal) models for sample size determination.
    • The shift towards normality-based methods in additive models warrants careful consideration for bioequivalence study design.

    Key Insights:

    • Parametric analysis in bioequivalence often relies on lognormal distribution assumptions within multiplicative models.
    • Emerging statistical methods offer sample size calculations for additive models assuming normality.

    Related Experiment Videos

    Outlook:

    • Future research should focus on the practical application and regulatory acceptance of normality-based sample size calculations in bioequivalence.
    • Further investigation into the robustness and efficiency of additive models compared to traditional multiplicative models is recommended.